Zai Lab (09688) rose more than 3%, with the stock up 3.36% to HK$16.9 at the time of reporting. Turnover reached HK$27.1925 million. The increase follows a recent announcement by the company via its official social media account regarding a global clinical research collaboration with Amgen. The partnership aims to evaluate Zai Lab's clinical-stage antibody-drug conjugate (ADC) targeting delta-like ligand 3 (DLL3), zocilurtatug pelitecan (Zoci, formerly ZL-1310), in combination with Amgen's IMDELLTRA® (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE®) therapy, for treating patients with extensive-stage small cell lung cancer (ES-SCLC). Under the agreement, Amgen will sponsor a global Phase 1b study to assess the safety and efficacy of the Zoci and IMDELLTRA® combination in ES-SCLC patients. Zai Lab will retain full ownership of Zoci and will supply the investigational drug for the clinical study. Analysts at CICC noted that Zai Lab initiated a global registrational Phase III clinical trial for Zoci in second- and third-line SCLC by the end of 2025. The trial's treatment arm includes patients in the second-line setting after progression on platinum-based chemotherapy and third-line patients post-Tarla therapy, with chemotherapy as the control. The study plans to enroll 480 participants, with primary endpoints being overall response rate (ORR) and overall survival (OS). The company believes that, pending supportive data, it could submit an accelerated approval application in the United States by 2027. Furthermore, the company plans to release data for second-line-plus SCLC with intracranial involvement and extrapulmonary neuroendocrine carcinoma in the first half of 2026, followed by Phase I combination data for first-line SCLC (with PD-L1 inhibitor, with or without chemotherapy) in the second half of 2026. Monitoring the readout of this relevant data is recommended.